|
US20030212021A1
(en)
*
|
2001-01-25 |
2003-11-13 |
Frost Gregory I. |
Myeloid colony stimulating factor and uses thereof
|
|
US7544499B2
(en)
|
2002-12-16 |
2009-06-09 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP2330213A1
(en)
|
2003-03-05 |
2011-06-08 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
*
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
US7572613B2
(en)
*
|
2004-06-25 |
2009-08-11 |
Klein Jeffrey A |
Drug delivery system for accelerated subcutaneous absorption
|
|
CN103860582A
(zh)
*
|
2004-12-30 |
2014-06-18 |
建新公司 |
用于关节内粘弹性补充的方案
|
|
CN103145837A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
US8168206B1
(en)
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
|
PL1976877T5
(pl)
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
|
KR20090006153A
(ko)
*
|
2006-03-31 |
2009-01-14 |
큐엘티 플러그 딜리버리, 인코포레이티드 |
비루관계에 대한 약물 전달 방법, 구조, 및 조성물
|
|
HUE052220T2
(hu)
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin-13 kötõfehérjék
|
|
NZ576032A
(en)
|
2006-10-12 |
2012-03-30 |
Genentech Inc |
Antibodies to lymphotoxin-alpha
|
|
US20080160003A1
(en)
*
|
2006-10-31 |
2008-07-03 |
University Of Delaware |
Fertility Enhancement Using Lipid Carriers and Bioactive Molecules
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
WO2009037566A2
(en)
*
|
2007-06-19 |
2009-03-26 |
Uvarkina Tamara P |
Hyaluronidase and method of use thereof
|
|
US9011361B2
(en)
*
|
2007-09-07 |
2015-04-21 |
Mati Therapeutics Inc. |
Lacrimal implant detection
|
|
WO2009061482A2
(en)
*
|
2007-11-06 |
2009-05-14 |
Weg Stuart L |
Anesthetic composition, formulation and method of use
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
CN101970650B
(zh)
*
|
2008-03-06 |
2017-07-25 |
哈洛齐梅公司 |
可溶性透明质酸酶的大规模生产
|
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
US20090311237A1
(en)
*
|
2008-04-14 |
2009-12-17 |
Frost Gregory I |
Combination therapy using a soluble hyaluronidase and a bisphosphonate
|
|
WO2009128917A2
(en)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
TWI394580B
(zh)
*
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
CN102089430B
(zh)
|
2008-05-09 |
2015-02-04 |
Abbvie公司 |
针对渐进性糖化终极产物受体(rage)的抗体及其用途
|
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
KR20110040886A
(ko)
|
2008-07-08 |
2011-04-20 |
아보트 러보러터리즈 |
프로스타글란딘 e2 결합 단백질 및 이의 용도
|
|
AR077718A1
(es)
*
|
2008-07-15 |
2011-09-21 |
Genentech Inc |
Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
|
|
ES2413492T3
(es)
*
|
2008-10-14 |
2013-07-16 |
Burgard, Gunther, Dr. |
Uso de hialuronidasa para la prevención o el tratamiento de la hipertensión arterial
|
|
GB0819883D0
(en)
|
2008-10-29 |
2008-12-03 |
Azyme Res As |
Product and uses
|
|
CN102307993B
(zh)
*
|
2008-12-09 |
2014-06-25 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
|
AU2013202000B2
(en)
*
|
2008-12-09 |
2015-07-30 |
Halozyme, Inc. |
Extended soluble PH20 polypeptides and uses thereof
|
|
US20100209558A1
(en)
*
|
2009-02-19 |
2010-08-19 |
General Nutrition Corporation |
Dietary ingredient with enhanced bioavailability
|
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
|
JP5649589B2
(ja)
*
|
2009-03-06 |
2015-01-07 |
ハロザイム インコーポレイテッド |
マトリックスメタロプロテアーゼ1の温度感受性突然変異体およびその使用
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
DE102009003291A1
(de)
*
|
2009-05-20 |
2010-12-30 |
Henkel Ag & Co. Kgaa |
Kosmetische Zusammensetzung und Verformungsverfahren für keratinische Fasern
|
|
WO2010138918A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Pacira Pharmaceuticals, Inc. |
Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
|
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
|
US20120100555A1
(en)
*
|
2009-06-29 |
2012-04-26 |
Martin James Lear |
Synthesis And Use Of Fluorophore-Tagged Antimalarials
|
|
US8513259B2
(en)
|
2009-07-03 |
2013-08-20 |
Jdp Therapeutics, Inc. |
Non-sedating antihistamine injection formulations and methods of use thereof
|
|
US8263581B2
(en)
|
2009-07-03 |
2012-09-11 |
Jdp Therapeutics, Inc. |
Non-sedating antihistamine injection formulations and methods of use thereof
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
PT2477603E
(pt)
*
|
2009-09-17 |
2016-06-16 |
Baxalta Inc |
Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
|
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
PH12012501070A1
(en)
|
2009-12-08 |
2017-08-23 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
TWI500427B
(zh)
|
2010-05-14 |
2015-09-21 |
Abbvie Inc |
Il-1結合蛋白
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
DK2595624T3
(en)
|
2010-07-20 |
2018-03-26 |
Halozyme Inc |
Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
KR20130096731A
(ko)
|
2010-09-08 |
2013-08-30 |
할로자임, 아이엔씨 |
조건부 활성 치료적 단백질을 평가,확인 또는 진화시키는 방법
|
|
US8404268B2
(en)
|
2010-10-26 |
2013-03-26 |
Kyphon Sarl |
Locally targeted anti-fibrotic agents and methods of use
|
|
US8740982B2
(en)
|
2010-10-26 |
2014-06-03 |
Kyphon Sarl |
Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
|
|
US9414930B2
(en)
|
2010-10-26 |
2016-08-16 |
Kyphon SÀRL |
Activatable devices containing a chemonucleolysis agent
|
|
JP6194248B2
(ja)
|
2010-10-28 |
2017-09-06 |
パシラ ファーマシューティカルズ インコーポレーテッド |
非ステロイド性抗炎症薬の徐放性処方物
|
|
KR101933197B1
(ko)
|
2010-11-08 |
2018-12-27 |
제넨테크, 인크. |
피하 투여용 항―il―6 수용체 항체
|
|
MX2013007332A
(es)
|
2010-12-21 |
2014-01-23 |
Abbvie Inc |
Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
|
|
WO2012106363A2
(en)
|
2011-01-31 |
2012-08-09 |
Intellect Neurosciences Inc. |
Treatment of tauopathies
|
|
EP2907504B1
(en)
|
2011-02-08 |
2017-06-28 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
EP2720712B1
(en)
|
2011-06-17 |
2016-03-02 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
US20130022592A1
(en)
|
2011-06-17 |
2013-01-24 |
Daniel Edward Vaughn |
Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
|
|
SG10201505454SA
(en)
|
2011-07-13 |
2015-09-29 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
|
CA2853358A1
(en)
|
2011-10-24 |
2013-05-02 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
|
UY34410A
(es)
|
2011-10-24 |
2013-05-31 |
Abbvie Inc |
Inmunoligantes biespecificos dirigidos contra tnf
|
|
AR088513A1
(es)
|
2011-10-24 |
2014-06-18 |
Abbvie Inc |
Inmunoenlazantes dirigidos contra esclerostina
|
|
CN104136462B
(zh)
|
2011-12-14 |
2017-06-09 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗铁相关病症的组合物和方法
|
|
MX357708B
(es)
|
2011-12-14 |
2018-07-20 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
SG11201403714TA
(en)
|
2011-12-30 |
2014-07-30 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
EP2833905B1
(en)
|
2012-04-04 |
2018-05-02 |
Halozyme, Inc. |
Combination therapy with hyaluronidase and a tumor-targeted taxane
|
|
EP2843051B1
(en)
|
2012-04-23 |
2018-06-06 |
GeneFrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
|
WO2014018747A2
(en)
|
2012-07-26 |
2014-01-30 |
Momenta Pharmaceuticals, Inc. |
Glycoproteins with anti-inflammatory properties
|
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
KR101454646B1
(ko)
*
|
2012-11-05 |
2014-10-27 |
(주)한국비엠아이 |
히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제
|
|
CN104937099B
(zh)
|
2012-11-09 |
2018-03-30 |
基因先端领域株式会社 |
用于治疗癌症的抗adam28抗体
|
|
WO2014107745A1
(en)
|
2013-01-07 |
2014-07-10 |
Halozyme, Inc. |
Metal sensitive mutants of matrix metalloproteases and uses thereof
|
|
US9789091B2
(en)
|
2013-03-14 |
2017-10-17 |
University Of Massachusetts |
Methods of inhibiting cataracts and presbyopia
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
TWI476203B
(zh)
|
2013-03-18 |
2015-03-11 |
Ind Tech Res Inst |
醣類的分離方法
|
|
EP2981283A4
(en)
|
2013-04-03 |
2017-07-05 |
Cedars-Sinai Medical Center |
Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
|
|
ES2708759T3
(es)
|
2013-05-13 |
2019-04-11 |
Momenta Pharmaceuticals Inc |
Procedimientos para el tratamiento de la neurodegeneración
|
|
EP3003372B1
(en)
|
2013-06-07 |
2019-10-09 |
Duke University |
Inhibitors of complement factor h
|
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
|
CA2917102A1
(en)
|
2013-07-03 |
2015-01-08 |
City Of Hope |
Anticancer combinations
|
|
CA2920835A1
(en)
|
2013-08-20 |
2015-02-26 |
Anutra Medical, Inc. |
Syringe fill system and method
|
|
US9968623B2
(en)
*
|
2013-08-29 |
2018-05-15 |
Lanny Leo Johnson |
Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
CA2927525C
(en)
|
2013-10-15 |
2023-01-31 |
Genefrontier Corporation |
Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
|
|
EP3058084A4
(en)
|
2013-10-16 |
2017-07-05 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
|
TW201536320A
(zh)
|
2013-12-02 |
2015-10-01 |
Abbvie Inc |
治療骨性關節炎之組合物及方法
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
|
TWI731535B
(zh)
|
2014-03-21 |
2021-06-21 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
|
US10117886B2
(en)
|
2014-05-30 |
2018-11-06 |
Hao Cheng |
Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
|
|
USD763433S1
(en)
|
2014-06-06 |
2016-08-09 |
Anutra Medical, Inc. |
Delivery system cassette
|
|
USD774182S1
(en)
|
2014-06-06 |
2016-12-13 |
Anutra Medical, Inc. |
Anesthetic delivery device
|
|
USD750768S1
(en)
|
2014-06-06 |
2016-03-01 |
Anutra Medical, Inc. |
Fluid administration syringe
|
|
US20160002326A1
(en)
|
2014-06-10 |
2016-01-07 |
Abbvie Inc. |
Compositions and methods for treating rheumatoid arthritis
|
|
WO2016011262A1
(en)
*
|
2014-07-16 |
2016-01-21 |
New York University |
Use of hyaluronidase for treatment of muscle stiffness
|
|
EP3186281B1
(en)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
WO2016040294A2
(en)
|
2014-09-09 |
2016-03-17 |
Janssen Biotech, Inc. |
Combination therapies with anti-cd38 antibodies
|
|
EA035414B1
(ru)
*
|
2014-09-18 |
2020-06-10 |
Шондронест Са |
Комбинация, содержащая гликозаминогликаны и белки
|
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
|
AU2015332533B2
(en)
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|
|
PE20171094A1
(es)
|
2014-12-04 |
2017-08-07 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
WO2016137471A1
(en)
*
|
2015-02-26 |
2016-09-01 |
Nantpharma, Llc |
Method for enhanced heparin quality
|
|
US9981021B1
(en)
|
2015-04-09 |
2018-05-29 |
Kinetiq, Inc. |
Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
JP6518917B2
(ja)
|
2015-05-29 |
2019-05-29 |
アッヴィ・インコーポレイテッド |
抗cd40抗体およびその使用
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
|
CN107708734B
(zh)
*
|
2015-06-22 |
2022-01-11 |
詹森生物科技公司 |
用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
|
|
EP3313441B1
(en)
|
2015-06-24 |
2024-02-21 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
CA2998183A1
(en)
|
2015-09-11 |
2017-03-16 |
AbbVie Deutschland GmbH & Co. KG |
Methods for treating relapsing forms of multiple sclerosis
|
|
JP7027321B2
(ja)
|
2015-11-03 |
2022-03-01 |
ヤンセン バイオテツク,インコーポレーテツド |
抗cd38抗体の皮下製剤及びその使用
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
PE20181070A1
(es)
|
2015-11-13 |
2018-07-04 |
Univ Massachusetts |
Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia
|
|
ITUB20159209A1
(it)
*
|
2015-12-21 |
2017-06-21 |
Fidia Farm Spa |
Nanosistemi per il trasporto controllato di molecole attive a fini diagnostici, prognostici e terapeutici
|
|
US10493247B2
(en)
|
2016-03-15 |
2019-12-03 |
Medtronic Holding Company Sàrl |
Devices for delivering a chemical denervation agent and methods of use
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
TW202523689A
(zh)
|
2016-06-01 |
2025-06-16 |
美商艾伯維有限公司 |
治療脊髓損傷及疼痛之方法
|
|
RS61828B1
(sr)
|
2016-06-08 |
2021-06-30 |
Abbvie Inc |
Anti-b7-h3 antitela i antitelske konjugacije lekova
|
|
JP2019526529A
(ja)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
抗b7−h3抗体及び抗体薬物コンジュゲート
|
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
|
JP7217700B2
(ja)
|
2016-09-13 |
2023-02-03 |
アラーガン、インコーポレイテッド |
安定化非タンパク質クロストリジウム毒素組成物
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
TWI826360B
(zh)
|
2016-11-17 |
2023-12-21 |
美商艾歐凡斯生物治療公司 |
殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
|
|
CN109982709A
(zh)
*
|
2016-11-17 |
2019-07-05 |
Vcn生物科学有限公司 |
病毒载体在治疗视网膜母细胞瘤中的用途
|
|
CN109983013A
(zh)
|
2016-11-18 |
2019-07-05 |
帕西拉制药有限公司 |
美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
|
|
WO2018098370A1
(en)
|
2016-11-23 |
2018-05-31 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
|
DK3570884T3
(da)
|
2017-01-17 |
2020-11-30 |
Genentech Inc |
Subkutane HER2-antistofformuleringer
|
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
RU2651756C1
(ru)
*
|
2017-05-10 |
2018-04-23 |
Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ |
Препарат для предотвращения образования глиальных рубцов
|
|
EP3694884A1
(en)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
US11618787B2
(en)
|
2017-10-31 |
2023-04-04 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
KR20200084880A
(ko)
|
2017-11-06 |
2020-07-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2019133166A1
(en)
*
|
2017-12-29 |
2019-07-04 |
The Trustees Of Columbia University In The City Of New York |
Hyaluronidase for the prevention, treatment, reduction and/or abolishment of cerebral edema and intracranial pressure
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN112513079A
(zh)
|
2018-03-13 |
2021-03-16 |
拉巴斯大学医院生物医学研究基金会 |
用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019182745A1
(en)
|
2018-03-19 |
2019-09-26 |
Bryn Pharma, LLC |
Epinephrine spray formulations
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
Micaおよび/またはmicbに対する抗体ならびにそれらの使用
|
|
EP3774911A1
(en)
|
2018-03-30 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
|
JP6946575B2
(ja)
|
2018-04-24 |
2021-10-06 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
眼の状態の治療のためのピロカルピン塩酸塩の使用
|
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
WO2019220368A1
(en)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
CN112654642B
(zh)
*
|
2018-06-01 |
2023-04-28 |
Musc研究发展基金会 |
蛋白质和细胞的聚糖分析
|
|
MX2020013923A
(es)
|
2018-06-29 |
2021-03-29 |
Apitbio Inc |
Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
MX2020009824A
(es)
|
2018-07-25 |
2021-01-15 |
Alteogen Inc |
Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
|
|
US20210395392A1
(en)
|
2018-10-09 |
2021-12-23 |
Bristol-Myers Squibb Company |
Anti-mertk antibodies for treating cancer
|
|
MA53920A
(fr)
|
2018-10-17 |
2021-09-15 |
Janssen Biotech Inc |
Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
|
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
|
WO2020092546A1
(en)
|
2018-10-30 |
2020-05-07 |
Alexion Pharmaceuticals, Inc. |
Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
|
|
CN113015805B
(zh)
|
2018-11-13 |
2024-12-03 |
詹森生物科技公司 |
抗cd38抗体产生期间的痕量金属的控制
|
|
CN109679823B
(zh)
*
|
2018-11-19 |
2022-03-15 |
江苏汇先医药技术有限公司 |
一种用于生物分子、细胞或细菌的捕获材料及捕获筛
|
|
SG11202109122SA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Anti-tcr antibody molecules and uses thereof
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN112203642B
(zh)
*
|
2019-03-25 |
2025-03-07 |
阿特根公司 |
用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
CN113874078B
(zh)
|
2019-04-05 |
2025-05-06 |
Tauc3生物制品有限公司 |
抗tauc3抗体及其应用
|
|
HUE071637T2
(hu)
*
|
2019-05-07 |
2025-09-28 |
Genzyme Corp |
Eljárások prodrogkészítményben lévõ drog koncentrációjának mennyiségi meghatározására
|
|
US20220193149A1
(en)
*
|
2019-05-16 |
2022-06-23 |
City Of Hope |
Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery
|
|
US12269021B2
(en)
*
|
2019-05-24 |
2025-04-08 |
Glytech, Inc. |
Artificial protein catalyst
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
CN114651003A
(zh)
|
2019-09-10 |
2022-06-21 |
黑曜石疗法公司 |
用于可调调节的ca2-il15融合蛋白
|
|
CN114728070A
(zh)
|
2019-09-25 |
2022-07-08 |
百时美施贵宝公司 |
用于癌症疗法的复合生物标记物
|
|
EP4017524A4
(en)
*
|
2019-10-15 |
2022-09-21 |
Standard of Care Corporation |
COMPOSITIONS WITH HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT THEREOF
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
EP4054723A1
(en)
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
JP2023504748A
(ja)
|
2019-12-09 |
2023-02-06 |
ジェネンテック, インコーポレイテッド |
抗pd-l1抗体製剤
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
TW202615652A
(zh)
|
2020-01-23 |
2026-04-16 |
南韓商阿特根公司 |
新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
|
|
WO2021165226A1
(en)
|
2020-02-17 |
2021-08-26 |
Biotest Ag |
Subcutaneous administration of factor viii
|
|
AU2021244200A1
(en)
|
2020-03-23 |
2022-11-24 |
Bristol-Myers Squibb Company |
Anti-CCR8 antibodies for treating cancer
|
|
CN111529685A
(zh)
*
|
2020-04-21 |
2020-08-14 |
厦门诺康得生物科技有限公司 |
抗呼吸道病毒感染的鼻腔喷雾制剂
|
|
AU2021273014A1
(en)
|
2020-05-13 |
2022-11-17 |
AbbVie Deutschland GmbH & Co. KG |
Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
|
|
ES3075793T3
(en)
|
2020-05-13 |
2026-08-07 |
Disc Medicine Inc |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下(sc)施用抗c5抗体治疗补体相关病症
|
|
JP2023532122A
(ja)
|
2020-06-29 |
2023-07-26 |
ジェネンテック, インコーポレイテッド |
ペルツズマブにトラスツズマブを加えた固定用量配合剤
|
|
AU2021308283A1
(en)
|
2020-07-14 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Assays for fixed dose combinations
|
|
CA3181682A1
(en)
*
|
2020-07-17 |
2022-01-20 |
Anil Kapur |
Subcutaneous telomerase inhibitor compositions and methods for using same
|
|
WO2022031093A1
(ko)
*
|
2020-08-07 |
2022-02-10 |
(주)알테오젠 |
재조합 히알루로니다제의 생산 방법
|
|
CN111759732B
(zh)
*
|
2020-08-12 |
2024-12-06 |
河南省人民医院 |
一种用于外周血造血干细胞冻存的多通道连接管路及方法
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3190573A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Methods of detecting trbc1 or trbc2
|
|
MX2023002332A
(es)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
CN112168838A
(zh)
*
|
2020-10-23 |
2021-01-05 |
中国科学院动物研究所 |
透明质酸及其盐的治疗用途
|
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
|
US20220133861A1
(en)
*
|
2020-10-30 |
2022-05-05 |
Standard Of Care Corporation |
Hyaluronidase compositions and methods of using same to treat edema
|
|
US20230405001A1
(en)
*
|
2020-11-17 |
2023-12-21 |
Janssen Sciences Ireland Unlimited Company |
Treatment or prevention of hiv infection
|
|
WO2022109555A1
(en)
|
2020-11-17 |
2022-05-27 |
Janssen Sciences Ireland Unlimited Company |
Treatment or prevention of hiv infection
|
|
MX2023005760A
(es)
|
2020-11-17 |
2023-07-31 |
Janssen Sciences Ireland Unlimited Co |
Tratamiento o prevención de una enfermedad o trastorno.
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
AU2021416156A1
(en)
|
2020-12-28 |
2023-06-22 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
PT4267105T
(pt)
|
2020-12-28 |
2025-04-30 |
Bristol Myers Squibb Co |
Composições de anticorpos e métodos de utilização das mesmas
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
|
CN114350639B
(zh)
*
|
2021-03-05 |
2023-06-02 |
华熙生物科技股份有限公司 |
一种密码子优化的透明质酸水解酶基因及其表达
|
|
CN113025599B
(zh)
*
|
2021-04-02 |
2023-09-12 |
重庆科润生物医药研发有限公司 |
一种重组溶组织梭菌i型胶原酶及其制备方法和应用
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
|
TW202305009A
(zh)
|
2021-04-08 |
2023-02-01 |
美商默沙東有限責任公司 |
以皮下投予抗pd1抗體治療癌症之方法
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
US20220332822A1
(en)
|
2021-04-16 |
2022-10-20 |
Tiziana Life Sciences Plc |
Subcutaneous administration of antibodies for the treatment of disease
|
|
TW202308689A
(zh)
|
2021-04-21 |
2023-03-01 |
美商健生生物科技公司 |
高濃度的雙特異性抗體調配物
|
|
WO2022251645A1
(en)
|
2021-05-27 |
2022-12-01 |
Steiner Ventures Llc |
Hyaluronidase composition for intravenous administration and method of using the same
|
|
CN115671267A
(zh)
|
2021-07-23 |
2023-02-03 |
上海宝济药业有限公司 |
一种皮下抗生素药物组合物
|
|
CN117693362A
(zh)
*
|
2021-08-02 |
2024-03-12 |
甘李药业股份有限公司 |
含有抗il-4r抗体的稳定制剂
|
|
WO2023012515A2
(en)
|
2021-08-02 |
2023-02-09 |
argenx BV |
Subcutaneous unit dosage forms
|
|
WO2023042096A1
(en)
|
2021-09-14 |
2023-03-23 |
Takeda Pharmaceutical Company Limited |
Facilitated delivery of concentrated antibody formulations using hyaluronidase
|
|
CA3236277A1
(en)
*
|
2021-10-29 |
2023-05-04 |
Soon Jae Park |
Pharmaceutical composition comprising human hyaluronidase ph20 and drug
|
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
US20230134748A1
(en)
|
2021-11-03 |
2023-05-04 |
Janssen Biotech, Inc. |
Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
|
|
EP4426437A4
(en)
|
2021-11-03 |
2025-09-17 |
Janssen Biotech Inc |
METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
|
|
US20250075009A1
(en)
*
|
2022-01-14 |
2025-03-06 |
Jenkem Technology Co., Ltd. (Tianjin) |
Hyaluronic acid derivative or salt thereof, and preparation method therefor and application thereof
|
|
AU2023213937A1
(en)
|
2022-01-26 |
2024-07-18 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
KR20240153583A
(ko)
|
2022-02-25 |
2024-10-23 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암종에 대한 병용 요법
|
|
US20250099612A1
(en)
|
2022-03-01 |
2025-03-27 |
Exuma Biotech Corp. |
Viral particles with membrane-bound hyaluronidase
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN114634920B
(zh)
*
|
2022-03-24 |
2024-02-27 |
江南大学 |
一种产人源透明质酸酶ph20的重组毕赤酵母及其构建方法
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN119403543A
(zh)
|
2022-04-22 |
2025-02-07 |
爱尔兰詹森科学公司 |
液体组合物
|
|
WO2023203257A1
(en)
|
2022-04-22 |
2023-10-26 |
Janssen Sciences Ireland Unlimited Company |
Freeze dried compositions
|
|
CN119948055A
(zh)
|
2022-05-24 |
2025-05-06 |
百时美施贵宝公司 |
结合人ccr8的抗体
|
|
AU2023281061A1
(en)
|
2022-06-02 |
2024-12-05 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
WO2023249408A1
(ko)
*
|
2022-06-22 |
2023-12-28 |
(주)알테오젠 |
N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
|
|
IL320562A
(en)
|
2022-11-02 |
2025-07-01 |
Janssen Biotech Inc |
Cancer treatment methods
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
KR20250134732A
(ko)
|
2022-12-22 |
2025-09-11 |
할로자임, 아이엔씨 |
대용량 투여를 위한 히알루로니다아제 효소 제형
|
|
WO2024189048A1
(en)
|
2023-03-13 |
2024-09-19 |
Heidelberg Pharma Research Gmbh |
Subcutaneously administered antibody-drug conjugates for use in cancer treatment
|
|
CN116253809B
(zh)
*
|
2023-04-19 |
2024-11-05 |
广州润虹医药科技股份有限公司 |
一种去除壳聚糖中内毒素的方法
|
|
KR20260085106A
(ko)
*
|
2023-09-12 |
2026-06-08 |
센트리메드, 인코포레이티드 |
가용성 재조합 인간 포도플라닌 수용체
|
|
AU2024351533A1
(en)
|
2023-09-26 |
2026-03-19 |
Takeda Pharmaceutical Company Limited |
IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
|
|
EP4791505A1
(en)
|
2023-10-12 |
2026-08-19 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma comprising an anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone
|
|
WO2025096611A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Siemens Healthcare Diagnostics Inc. |
Reagent compositions for immunoassays and use of the same in detection of cancer antigen 19-9
|
|
CN117887691B
(zh)
*
|
2023-12-27 |
2024-07-12 |
山东福瑞达医药集团有限公司 |
一种透明质酸酶融合蛋白、酵母工程菌及构建方法与应用
|
|
WO2025155877A2
(en)
|
2024-01-18 |
2025-07-24 |
The Regents Of The University Of California |
Antibodies binding to pad4 and uses thereof
|
|
WO2025158277A1
(en)
|
2024-01-22 |
2025-07-31 |
Janssen Biotech, Inc. |
Use of amivantamab to treat head and neck cancer
|
|
WO2025188901A1
(en)
|
2024-03-05 |
2025-09-12 |
Halozyme, Inc. |
Combination therapy with antibody-drug conjugates and hyaluronidases
|
|
WO2025191459A1
(en)
|
2024-03-11 |
2025-09-18 |
Janssen Biotech, Inc. |
Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
|
|
KR102687341B1
(ko)
*
|
2024-04-09 |
2024-07-23 |
주식회사 휴온스랩 |
온전한 형태의 히알루로니다제의 생산방법
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
TW202615468A
(zh)
|
2024-05-29 |
2026-04-16 |
美商健生生物科技公司 |
局部晚期或轉移性egfr突變之非小細胞肺癌之治療
|
|
WO2025262427A1
(en)
|
2024-06-19 |
2025-12-26 |
Levicept Limited |
Injectable formulation
|
|
TW202617771A
(zh)
|
2024-06-21 |
2026-05-01 |
美商艾普吉醫療股份有限公司 |
結合il-13之抗體及結合ox40l之抗體
|
|
WO2025264972A1
(en)
|
2024-06-21 |
2025-12-26 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-4r alpha and antibodies that bind
|
|
WO2026022733A1
(en)
|
2024-07-23 |
2026-01-29 |
Janssen Biotech, Inc. |
Combination therapies for the treatment of colorectal cancer
|
|
WO2026022739A1
(en)
|
2024-07-23 |
2026-01-29 |
Janssen Biotech, Inc. |
Combination therapies for the treatment of colorectal cancer
|
|
WO2026028163A1
(en)
|
2024-08-01 |
2026-02-05 |
Janssen Biotech, Inc. |
Methods for treating high-risk smoldering multiple myeloma
|
|
CN122206451A
(zh)
|
2024-08-01 |
2026-06-12 |
詹森生物科技公司 |
用于治疗多发性骨髓瘤的达雷木单抗、硼替佐米、来那度胺和地塞米松
|
|
US20260102490A1
(en)
|
2024-10-11 |
2026-04-16 |
Janssen Biotech, Inc. |
Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
|
|
WO2026085419A2
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
|
|
WO2026085417A2
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
|
|
WO2026085414A1
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
|
|
CN118969102B
(zh)
*
|
2024-10-18 |
2025-02-18 |
南京汉卫公共卫生研究院有限公司 |
一种基于数据融合分析的肿瘤组织分子智能分析识别系统
|
|
WO2026085415A1
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
|
|
WO2026120486A1
(en)
|
2024-12-02 |
2026-06-11 |
Halozyme, Inc. |
Soluble hyaluronidase and production thereof
|
|
WO2026122407A1
(en)
|
2024-12-04 |
2026-06-11 |
Merck Sharp & Dohme Llc |
Amyloid beta binder, and uses thereof
|
|
WO2026124468A1
(en)
|
2024-12-10 |
2026-06-18 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Pharmaceutical combinations, their uses and therapeutic methods
|
|
WO2026145588A1
(en)
|
2024-12-31 |
2026-07-09 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Use of egfr/c-met bispecific binding protein
|
|
WO2026152008A1
(en)
|
2025-01-10 |
2026-07-16 |
Oric Pharmaceuticals, Inc. |
Enozertinib for treating epidermal growth factor receptor (egfr) exon 20 mutant nsclc in combination with amivantamab
|
|
WO2026156021A1
(en)
|
2025-01-16 |
2026-07-23 |
Merck Sharp & Dohme Llc |
Bispecific antibody constructs that bind alpp/alppl2 and cd3
|
|
WO2026163248A1
(en)
|
2025-01-31 |
2026-08-06 |
Biocon Biologics Limited |
Recombinant human hyaluronidase polypeptide variants, method of preparation and pharmaceutical compositions thereof
|